Clarient plans to commercialize Applied Genomics' five-antibody immunohistochemistry test for non-small cell lung cancer, called Pulmotype, within its network of pathologists by the first quarter of 2010.
At a meeting hosted by the Partners HealthCare Center for Personalized Genetic Medicine last month, the events leading up to the re-labeling for colorectal cancer drugs Vectibix and Erbitux sparked discussion among participants about what Amgen and Bristol-Myers Squibb/ImClone knew about the drugs and when.
Although this update is only for Plavix, the FDA is mulling whether to update the labeling for CYP2C19-inhibiting drugs, and is looking at whether drug response is compromised in all patients or only those with certain CYP2C19 mutations.
According to Woodcock, comparative effectiveness research and personalized medicine can come together in conducting community-based research. But for that, the US research infrastructure needs to be improved.
According to Quest, Scripps Health is "the first health system in the US to deploy this genetic testing service for coronary stent patients" receiving Plavix. The testing will initially be available for stent procedure patients presenting to Scripps Green Hospital in San Diego.
Medco's study will examine whether the 70 to 75 percent of patients who are "extensive metabolizers" of Bristol-Myers Squibb's Plavix will have "comparable outcomes" to patients taking Eli Lilly's more expensive Effient.
In acquiring DxS, Qiagen is attempting to increase its presence in molecular diagnostic-based personalized healthcare. Meantime, coming under the Qiagen umbrella is likely to provide a relatively small personalized medicine firm like DxS a global reach and more negotiating clout with large pharma and biotechs.
Researchers from Celera and Medco are investigating whether carriers of KIF6 who are made aware of their genetic risk factor and therapeutic advantage will stick to taking their statin drugs. But will it sway insurers?
Qiagen said that the acquisition, along with the fact that it has more than 15 companion diagnostic collaborations with pharma companies, provides it with a leading position in the personalized healthcare market.
The two companies announced plans to develop a companion diagnostic to predict whether non-squamous non-small cell lung cancer patients can benefit from combination treatment with Alimta and cisplatin based on the thymidylate synthase biomarker.
According to an editorial in the New England Journal of Medicine, two new studies suggest "that EGFR mutations represent favorable prognostic markers of survival and are predictive of tumor shrinkage, but the evidence that they can predict a differential effect of tyrosine kinase inhibitors on survival is incomplete."
Pfizer has previously touted PF-02341066 as "the first agent in clinical development that selectively targets a unique genetic feature of cancer cells." The drug is currently in Phase III trials, while Abbott is in the process of designing validating trials for a companion test with the capability to detect ALK gene rearrangements.
Following the GWAS, researchers plan to conduct a prospective, randomized-controlled trial and form a pharmacogenomics consortium specifically focused on validating and discovering new gene-response variants for clopidogrel.
A team of scientists led by researchers at the University of Maryland Medical School reports today in JAMA that CYP2C19*2 influences Plavix treatment response as well as the frequency of coronary problems in those at higher risk of such events.